INTRODUCTION T
HERE IS INTENSE INTEREST in the development of an effective vaccine able to curtail the continuing expansion of the HIV-1 epidemic. The number of people infected worldwide is estimated to be nearly 42 million, with more than 90% living in developing countries, 10% of whom are in South Africa. 1 In South Africa it is estimated that approximately one in four pregnant women attending public antenatal clinics is infected. 2 HIV-1 subtype C has emerged as the most significant subtype globally and is associated with more than 50% of infections. 3 It is estimated that this subtype accounts for more than 95% of infections in the southern African region, where it is spread heterosexually. [4] [5] [6] [7] [8] [9] It is also the most common subtype in India. 10 Although the significance of genetic variation in vaccine efficacy is unresolved, there is some indication that it may be important. Although individuals vaccinated with a subtype Bbased HIV-1 vaccine can elicit cross-subtype cytotoxic T lymphocyte (CTL) reactivity 11 and CTLs from individuals infected with one subtype can lyse target cells infected with a different subtype, [12] [13] [14] [15] this cross-reactive response may be diminished when compared with intrasubtype responses. In a study of HIV-1-resistant sex workers in Nairobi, Kenya, RowlandJones et al. 16 found that there was preferential CTL recognition of subtype A or D peptides, compared with B peptides, and, similarly, preferential CTL recognition was demonstrated in infected individuals in Thailand when target cells were infected with matched subtypes. 15 In addition, comparison of well-characterised CTL epitopes shows a greater conservation within a subtype compared with between subtypes. 17 Until more is known about the effect of diversity on vaccine efficacy, it is prudent to develop vaccines to match the viruses circulating in the target population.
Of the many vaccine approaches, the ones furthest in clinical development are the recombinant canarypox vector vaccines, either individually or in combination with the gp120 protein subunit. A promising novel approach is the Venezuelan equine encephalitis virus (VEE) replicon particle (VRP) vaccine. This VRP delivers self-replicating, noninfectious RNA to the lymphoid tissue where the foreign gene is expressed. This approach has been shown to elicit both CTL and antibody responses and was able to reduce virus load and disease progression in an SIV challenge experiment. 18 This study aimed to identify representative, recently transmitted HIV-1 subtype C isolates for use in the development of vaccines targeted for South Africa and the southern African region, and to provide an efficient strategy for surveying sequence diversity among circulating viruses. Genes from these isolates were cloned into VRP expression vectors and tested for immunogenicity and function. Phase I vaccine trials of VRP vaccine expressing the selected subtype C Gag are planned in the United States and South Africa. This study is unique in that vaccine strains were selected to match the circulating viruses in proposed phase III trial sites in an effort to minimize the potential impact of viral genetic diversity on vaccine efficacy. While a consensus sequence provides the advantage of being, on average, closer to the circulating virus, it is a predicted sequence and may not be a functional gene. This may be disadvantageous for vaccines aimed at eliciting antibody responses. Utilizing genes from viable isolates also has the advantage in future testing of immune responses in vaccinees as it enables cross-reactive immunogenicity studies of homologous and heterologous strains.
MATERIALS AND METHODS

Patients
HIV-1-infected individuals, recruited from three provinces in South Africa, were classified into two groups according to the timing of infection.
Acute infections. Fifteen blood samples were obtained from female sex workers from five truck stops located along the road between Johannesburg and Durban (Du prefix; Table 1 ). At the time of this study, women were being tested monthly for sexually transmitted infections as part of their participation in a WILLIAMSON ET AL. 134 Abbreviations: NSI, Nonsyncytium inducing; SI, syncytium inducing. a All women were screened monthly for HIV-1 infection, except for Du172, whose last negative ELISA and first positive ELISA were 4 months apart. Estimated months after seroconversion is taken from the midpoint between the last negative ELISA and first positive ELISA.
b -, Negative (PCR or culture). c Viral isolates were taken from blood samples of six of the women listed. In four cases later blood samples were used: Du174 (20.4 months), Du179 (21.9 months), Du201 (12.6 months), and Du422 (4.4 months). Viral isolates could not be made from the PBMCs of five of the women listed.
phase III HIV-1 prevention microbicide trial. 19, 20 HIV-1 infection was assessed by enzyme-linked immunosorbent assay (ELISA) (Abbott, Chicago, IL), and confirmed with a Vironostika HIV Uniform II micro-ELISA 4 system (Omnimed, Madison, WI). Viral load was measured by a Bayer HIV-1 RNA 3.0 assay (bDNA) (Bayer Diagnostics, Puteaux Cedex, France).
Prevalent, asymptomatic infections. Blood samples were collected from individuals who were clinically well, the majority of whom had CD4
1 cell counts greater than 500 cells/ml. Seven samples were collected from women attending an antenatal clinic in Johannesburg (GG prefix), and nine samples were collected from men attending a sexually transmitted disease (STD) clinic at West Driefontein gold mine, Carltonville (RB prefix). Two additional samples from outpatient clinics in Cape Town (CT prefix) were included in this group.
Virus isolation and characterization
HIV-1 was isolated from peripheral blood mononuclear cells (PBMCs), using standard coculture techniques with mitogenactivated donor PBMCs. 21 . Isolates able to replicate in MT-2 cells as evidenced by the formation of syncytia were termed syncytium inducing (SI), whereas those that showed no syncytia within 6 days were termed nonsyncytium inducing (NSI). For coreceptor analysis, U87.CD4 cells stably transfected with either CCR5 or CXCR4 were used for viral infection (NIH Reference and Reagents Program, DAIDS, NIAID, NIH). 22 Isolates that produced syncytia and increasing concentrations of p24 antigen were considered positive for virus growth as previously described. 21 
RT-PCR of blood plasma
RNA was isolated from plasma (QIAamp viral RNA kit; Qiagen, Heidelberg, Germany) and cDNA to gag, pol, and env gene fragments was synthesized with reverse transcriptase followed by amplification by polymerase chain reaction (PCR) (GG and RB samples) or nested PCR (Du and CT samples). The following PCR primers were used (numbering is according to the HXB2 sequence, www://hiv-web.lanl.gov/): outer gag (59-AAATCTCTAGCAGTGGCG-3 9, positions 680-697; 59-ACCTCCAATTCCTCCTATC-3 9, positions 2329-2350); outer pol (59-AGGCTCTCTTAGACACAGGAG-3 9, positions 2313-2334; 59-CTTGTAATTCAGTCTTCTGATTTG-3 9, positions 3967-3990); outer env1 (59-AAAGGCTTAGGCATTTCC-3 9, positions 6201-6227; 59-CTACTCCCTCTGCTGCTG-3 9, positions 9067-9095); outer env2 (envB and envM primers). 23 The positions of the inner PCR primers/nonnested primers were as follows: gag1 (59-ATGGGTGCGAGAGCGTCAATATTA- For nested PCR, 3 ml of cDNA was added to 47 ml of PCR MasterMix (5 ml of 103 buffer, 1.5 U of Supertherm Taq, 4 ml of 10 mM dNTPs, 3 ml of 1.5 mM MgCl 2 , and 25 pmol of each primer) followed by PCR (one cycle at 94°C for 5 min; followed by 35 cycles of 94°C for 30 sec, 55°C for 30 sec, 72°C for 60 sec; then a final extension step of 72°C for 5 min). For nonnested PCR, 30 ml of PCR mix (13 Expand HF buffer with 1.5 mM MgCl 2 , 15 pmol of the downstream primer, 2 U of Expand High Fidelity enzyme mix [Boehringer, Mannheim, Germany]) was added to the room temperature reaction mixture (20 ml) . PCR was carried out as follows: one cycle at 94°C for 2 min and 45 sec; then 40 cycles at 94°C for 45 sec, 53°C for 45 sec, and 68°C for 1 min (after the first 10 cycles, 1 min was added to the 68°C extension cycle for the next 10 cycles, 2 min was added to the next 10 cycles, and 3 min was added for the last 10 cycles). The final extension step lasted for 7 min. For samples that showed poor amplification, the PCR product was reamplified after gel purification.
Sequencing and sequence analysis
The amplified DNA fragments were purified with a QIAquick PCR purification kit (Qiagen) and both strands were sequenced, using inner PCR primers and an ABI-Prism 377 DNA sequencer (Applied Biosystems, Foster City, CA). All sequences have been deposited in GenBank (AF543896-AF544010).
The nucleic acid sequences (gag [313 contiguous codons, 939 nucleotides], pol [278 contiguous codons, 834 nucleotides], and env [229 codons in two noncontiguous segments, 687 nucleotides]) were compared phylogenetically with a subtype C consensus sequence (Consensus C; http://hiv-web.lanl.gov), published subtype C sequences from the southern Africa region (http://hiv-web.lanl.gov), and the South African consensus sequence (Consensus_ZA) defining the most common nucleotide at each position in the sequence generated in this current work. Sequences were aligned with DNAMAN (version 4.0; Lynnon Biosoft, Vaudreuil-Dorion, Canada) with final manual adjustment. Neighbor-joining phylogenetic trees were generated by PHYLIP (Phylogeny Inference Package, version 3.56c; J. Felsenstein, Department of Genetics, University of Washington) using corrected distance matrices generated by Dnadist and the maximum likelihood model to incorporate different rates of transition and transversion (1.5). Trees were generated by Neighbor and drawn with TreeView (version 1.6.1; R. Page home page, http://taxonomy.zoology. gla.ac.uk/rod/rod.html).
Amino acid sequences were derived and used to determine a South African consensus sequence. Sequences were aligned with Pileup in the Genetics Computer Group (GCG) (Wisconsin Package version 10.0). Amino acid sequence analysis was performed with uncorrected distances, calculated by Distances.
Cloning of full-length genes
Full-length env and pol genes were generated by nested PCR from whole cell DNA purified from PBMC cultures infected with the Du151 isolate (low passage). DNA was extracted from pelleted cells with a QIAamp DNeasy tissue kit (Qiagen). The
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following primers were used: outer env (59-GAATTAG-GGAAAGAGCAGAAGACA-3 9, positions 6195-6218; 59-CAACTATGCTGCTTTTTGACCACT-3 9, positions 8807-8803); inner env (59-ATGAGAGTGATGGGGATACAG-3 9, positions 6225-6245; 59-TTATTGCAAAGCTGCTTCAAA-GCCCTGTCTTATTCTTC-3 9, positions 8758-8795); outer pol (59-ACCAAATGAAAGACTGTAC TGAG-39, positions 2050-2073; 59-ATTAGCTCTCCTTGAAACATACATATGGTG-3 9, positions 5119-5148); inner pol (59-TTTTTTAGGGAAAA-TTTGGCCTTC-39, positions 2058-2108; 59-AATCTTCATC-CTGTCTACCTGCCACAC-3 9, positions 5068-5094). PCR was carried out with the Expand Long Template PCR system (Boehringer) in a total volume of 50 ml containing 13 Expand PCR buffer 3, 2.5 ml of 10 mM dNTPs, 3 ml of 10 mM outer primers, 5 ml of DNA template, and 0.75 ml of the enzyme mix. PCR cycling was carried out as follows: one cycle at 94°C for 20 sec; 40 cycles at 94°C for 35 sec, 55°C for 45 sec, and 68°C for 2 min (after the first 10 cycles, 1 min was added to the 68°C extension step for the next 10 cycles, 2 min was added to the next 10 cycles, and 3 min was added for the last 10 cycles); the final extension time was 7 min. An aliquot of 1 ml of the first PCR was used for the second PCR, using the same PCR program but with the inner primers.
PCR products were purified with a QIAquick PCR purification kit (Qiagen) and were cloned into pT7 Blue after end conversion (Novagen, Madison, WI). Clones with inserts were identified by colony PCR and one clone was selected for each gene and sequenced in its entirety.
The full-length gag gene was generated by RT-PCR directly from RNA purified from plasma. The following primers were used for the outer nested PCR, with the outer reverse primer used for generating cDNA: o-gag-f (59-AAATCTCTAGCA-GTGGCG-39, positions 623-640) and o-gag-r (59-ACCTC-CAATTCCTCCTATC-3 9, positions 2390-2408). PCR cycles were as follows: 94°C for 5 min; then 35 cycles of 94°C for 30 sec, 55°C for 30 sec, and 72°C for 1 min; then 72°C for 5 min. The inner PCR primers were as follows: p17-eco-f (59-GAATTCATGGGTGCGAGAGCGTCAATA-3 9, positions 790-810) and I-gag-sal (59-GTCGACAATACTGTATCAT-CTGCTCCTG-39, positions 2329-2350). PCR cycles were as follows: 94°C for 5 min; then 5 cycles of 94°C for 30 sec, 55°C for 30 sec, and 72°C for 1 min; then 35 cycles of 94°C for 30 sec and 72°C for 1 min; then 72°C for 1 min. The PCR product was cloned into the pGEM-T Easy vector (Promega, Madison, WI) and positive clones were identified by restriction enzyme analysis. The full-length gene was sequenced in its entirety.
The full-length gag and env genes were cloned into the VEE replicon plasmid pERK, which is a derivative of pVR21 24 with additional restriction enzyme sites added (details available on request). The initial cloning step involved the PCR amplification of the full length genes to introduce a downstream flanking PacI site. Cloning of the gag gene included the incorporation of a mutation in the second gag codon to change it from a Gly codon to an Ala codon to ablate the encoded myristoylation signal.
The Du422 gag gene was also synthesized to allow the incorporation of codons representing those most frequently used in human cells (hu-gag; Qiagen Operon, Alameda, CA). This gene was cloned into pERK in the same manner as the viral genes.
Expression of full-length gag and env genes
BHK cells and VERO cells were infected with Du422 gagVRPs and hu-gag-VRPs at a multiplicity of infection of 3.5 infectious units per cell and incubated for 18 hr at 37°C. The cells were rinsed with phosphate-buffered saline (PBS) and resuspended in 0.5 ml of gel loading buffer containing sodium dodecyl sulfate (SDS) and 2-mercaptoethanol (Invitrogen, Carlsbad, CA). A cell lysate derived from approximately 2000 cells was loaded onto a 4-12% gradient acrylamide gel (Invitrogen) and the proteins were resolved by electrophoresis. Proteins were either stained in the gel with Coomassie Brilliant Blue or transferred onto a polyvinylidene difluoride (PVDF) membrane and probed with serum from an HIV-positive patient followed by goat antihuman-alkaline phosphatase (AP) conjugate. The membrane was developed with NBT/BCIP (Bio-Rad, Hercules, CA).
U87.CD4-CCR5 and U87.CD4-CXCR4 cells 22 
RESULTS
Patient populations and isolates used to determine HIV-1 diversity in South Africa
To characterize currently circulating viruses, this study targeted recent seroconvertors (Du prefix) and asymptomatic individuals with CD4 1 cell counts . 500 cells/ml (GG, RB, and CT prefix). Samples from the sex workers (Du cohort, n 5 15) working along the main trucking route between Durban and Johannesburg were likely to reflect isolates from multiple geographical origins as the truck drivers, who are the main clients, travel between provinces of South Africa and to other countries in southern Africa. To further ensure that isolates were representative of the genetic diversity within the country, samples were also collected from a second potential vaccine trial site, Chris Hani Baragwanath Hospital, Soweto (GG, n 5 7), as well as from West Driefontein gold mine, Carltonville (RB, n 5 9), and outpatient clinics in Cape Town (CT, n 5 2).
Most women in the Du cohort were identified within 1 year of infection, although two had seroconverted 14-16 months before sample collection (Du174 and Du179) ( Table 1) . The CD4 1 cell counts ranged from 367 to 841 cells/ml, and a wide range of viral loads was detected with high viral loads possibly reflecting viremia before the containment of viral replication. The median CD4
1 cell count for the asymptomatic group was 579 cells/ml, with all individuals having a CD4 1 cell count above 500 cells/ml, except for GG1, GG6, and GG10 who had CD4 1 cell counts between 383 and 423 cells/ml. CTSC1 and CTSC2 has CD4 1 cell counts of 271 and 390 cells/ml, respectively.
Virus isolation was attempted using blood samples from all 15 women in the Du cohort. Isolates were obtained from six women, using the baseline sample, and an additional four isolates were obtained with later samples (Table 1) . Nine of the 10 isolates were nonsyncytium inducing (NSI) in an MT-2 assay and replicated in the U87.CD4.CCR5 cells, indicating that they were R5 isolates. One isolate, Du179, induced syncytia (SI) when grown in MT-2 cells and also grew in both U87.CD4.CCR5 cells and U87.CD4.CXCR4 cells, indicating that it is a dual-tropic virus (R5X4). Biological clones of Du179 confirmed that it is a dual-tropic isolate and not a mixture of R5 and X4 variants (data not shown).
Phylogenetic analysis of segments of gag, pol, and env
A sequence-sampling strategy was devised in which two segments each of the gag, pol, and env genes were amplified, with the lengths of the amplicons selected to enable generation of the entire sequence in a single sequencing run. The two overlapping segments for gag and pol gave continuous sequence, 939 nucleotides and 834 nucleotides in length, respectively, whereas for env the two segments were discontinuous to avoid inclusion of the variable length regions V1, V2, V4, and V5, yielding 687 nucleotides in total. Sampling over the length of the genome permitted assessment of potential intersubtype recombination. All sequences were phylogenetically compared with reference subtypes 25 and were identified as subtype C in all regions analyzed, indicating a relative absence of intersubtype recombinants in this geographical region (results not shown).
To investigate the phylogenetic relationship among southern African viruses these sequences were then compared with all available subtype C sequences from the southern African region, as well as with the reference subtype C sequences (BR025 and ET2220) (Fig. 1) . A number of Botswanan clusters, previously identified, 9 were maintained in this analysis. Only limited internal structure was observed in all phylogenetic trees. However, a subcluster of South African sequences (Du422, Du151, Du281, Du467, Du457, GG3, RB28, Du123, Du368, and RB12) was largely preserved between the gag and env trees although this relationship was not supported by high bootstrap values. A significant relationship was detected between RB14 and RB18, and was supported by high bootstrap values in all regions analyzed, indicating epidemiological linkage.
The average nucleotide distance between the gag, pol, and env gene segments of subtype C viruses representing the southern African region was 7.8, 6.0, and 9.9%, respectively. This did not differ markedly from nucleotide distances between gene segments representing the viruses from South Africa only, which were 7.1, 5.1, and 11.3% for gag, pol, and env, respectively.
Selection of representative subtype C HIV-1 genes for vaccine development
To identify representative genes for candidate vaccines, each sequence was translated and compared with all the other amino acid sequences from this study; in addition, a consensus sequence was generated (South African consensus, SAcon) (Fig.  2) . In Gag, sequences were between 90.5 and 98.7% identical to the South African consensus sequence, with Du422 being closest to the consensus and the one chosen as the vaccine candidate. The amino acid sequence of the cloned full-length Du422 gag gene was 99.4% identical to the original sequence fragment derived from viral RNA in plasma. The remaining South African viruses were found to be between 90.5 and 96.7% identical to the Du422 gag clone. For 83% of the viruses, the Du422 clone sequence fell within the upper quartile, and in the upper half for all of them when each sequence was compared individually with all of the other sequences. On average, each isolate was 0.7% more similar to the South African consensus sequence than to the Du422 clone, except for one isolate (CTSC1), which was more similar to the clone.
As expected, the inferred Pol protein sequences showed the highest level of sequence identity among the three genes examined. Du151 was chosen as being closest to the South African consensus, at 98.9%. The Du151 Pol amino acid sequence inferred from the cloned pol gene shared between 96.8 and 93% sequence identity with all but one of the other viruses. When each sequence was compared with all the other viral sequences the Du151 clone was in the upper quartile 48% of the time and in the upper half 72% of the time. When each sequence was compared with the South African consensus sequence and the Du151 pol clone, there was an average of 1.6% greater similarity to the consensus sequence than to the clone sequence.
The inferred Env amino acid sequence displayed the greatest variability. Nine viral sequences shared between 92 and 95% identity with the South African consensus sequence. From this group we chose Du151 from the recent seroconverter cohort as this sample also gave a virus isolate that grew well in culture. The cloned sequence ranked in the upper quartile 54% of the time and in the upper half 77% of the time when each sequence was compared with all of the other viral sequences. All but one of the sequences were more similar to the South African consensus sequence than to the cloned sequence (average of 3.6%).
A comparison of the V3 amino acid sequences from the Du cohort showed Du179 to have an amino acid deletion at position 22 and an overall positive charge of 16, which is consistent with its SI phenotype. The remainder of the V3 amino acid sequences had charges of between 13 and 15, consistent with CCR5 usage.
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FIG. 1. Phylogenetic relationship generated from (A) partial gag (880 bp), (B) partial pol (776 bp), and (C) partial env (627 bp). Nucleic acid sequences from South Africa (ZA) (Du, GG, RB, CT prefix) were compared with those from Botswana (BW), Brazil (BR), Ethiopia (ET), and Uganda (UG), and with a South African subtype C consensus (Consensus_ZA) as well as a global subtype C consensus (Consensus C; http://hiv-web.lanl.gov). Sequences used to generate consensus South African sequence are shown in boldface, and vaccine isolates are underlined. Trees were generated by DNAdist and a maximum likelihood model with a transition-to-transversion ratio of 1.5 (PHYLIP). Scale bars indicate nucleotide sequence divergence. One hundred bootstrap analyses were performed with SEQBOOT, NEIGHBOR, and CONSENSE from the PHYLIP package. Bootstrap values over 75% are shown. A.UG.92UG037 was included as an outlier.
Expression of gag and env genes in the VEE vector
The full-length Du422 gag and Du151 env genes were cloned in the VEE replicon vector pERK. The second codon of gag was modified from Gly to Ala to ablate the myristoylation signal present at the N terminus of the Gag protein. This mutation causes Gag to be retained in the cell. [26] [27] [28] In parallel, the entire gag gene was chemically synthesized, altering the codons to represent optimized human codon usage (hu-gag). VEE replicon particles (VRPs) were generated as previously described 18 and used to infect BHK cells and VERO cells, and Gag expression was monitored after gel electrophoresis by both staining for protein mass and by Western blot analysis. Large amounts of p55 Gag protein accumulated in the cells (Fig. 3) . In addition, the optimization of codon usage did not affect the levels of expression. Equivalent levels of expression were seen in both cell types.
The gag-VRP was also tested for immunogenicity. A strong Gag-specific CTL response was detectable in cells cultured from the spleens of gag-VRP-immunized mice but not from the control mice immunized with PBS (Fig. 3C) . Spleen cells from both gag-VRP-and PBS-immunized mice cultured with syngeneic cells expressing the vaccinia virus vector alone showed no Gag-specific CTL response. gag-VRP-immunized mice developed a significant antibody response with an average reciprocal anti-Gag antibody titer, as measured by ELISA, in excess of 10 4 (data not shown). Env expression and function were assessed by using Du151 env-VRPs to infect BHK cells, U87.CD4-CXCR4 cells, U87.CD4-CCR5 cells, or mixtures of BHK cells with either of the other two cell types. Expression was assessed by Western blot analysis with antisera from subject Du151 to probe the blot. All three cell types expressed the full-length env gene product gp160 (Fig. 3A) . Unexpectedly, the cells expressing the cognate coreceptor accumulated more processed gp120. Figure 4 shows large syncytia that formed in the U87.CD4-CCR5-infected culture and an absence of syncytia in the U87.CD4-CXCR4-infected culture. These results are consistent with the coreceptor usage of the Du151 isolate (CCR5) and demonstrate that the cloned env gene encodes a functional protein.
DISCUSSION
Within an HIV-1 subtype, viruses are more closely related to each other than to those belonging to other subtypes, and consequently there are a greater number of shared amino acids and potential epitopes. It is therefore relevant to develop vaccines based on viral sequences circulating in the target population in an attempt to maximize the number of potentially crossreactive epitopes between the vaccine and the challenge virus. Two isolates were selected as the source of genes for inclusion into vaccines: Du422 for gag, and Du151 for pol and env ( Figs.  1 and 2 ). These genes have been cloned, and the gag and env genes have been used to express full-length viral proteins (Fig.  3) . Optimization of codon use for expression in human cells did not enhance expression of the gag gene in the robust VRP system. This suggests that improvements seen with codon optimization in other systems may be related to nuclear expression and/or export of the mRNA to the cytoplasm. Thus unaltered native HIV-1 genes may function well for expression using cytoplasmic expression vectors such as VEE and poxviruses. Du151 env and pol genes have also been codon optimized and are available for use. Genes from these vaccines strains are presently being included in a number of different vaccine approaches including VEE replicon particles (VRPs), 29 oligomeric proteins, 30 adeno-associated virus vectors, 31 DNA vaccines, the MVA (modified vaccine Ankara) vaccine vector, and the BCG vaccine vector. 32 Of these, VRPs represent the vaccine candidate furthest along in development, and phase I trials to assess the safety of VRPs expressing the Du422 gag gene are planned for South Africa and the United States. In an extension of this current investigation, the Du179 env gene has also been included in potential vaccines based on the presence of broadly cross-reacting neutralizing antibodies in this subject. 33 A similar strategy has been used to identify candidate vaccine genes for subtype B HIV-1 (L.-H. Ping and R. Swanstrom, unpublished observation).
An alternative approach to using representative viral sequences would be to construct a gene based on a consensus sequence, 9 ,34 although such a sequence may not necessarily be a functional gene. The viral sequences chosen from our sequence survey are similar to the consensus sequence (98.7, 98.9, and 95% similarity in Gag, Pol, and Env, respectively) and performed well when compared with a consensus sequence in cross-sectional distance comparisons (Fig. 2) . Still, there is an inherent sampling limitation in selecting viral sequences for inclusion in a vaccine because of incomplete knowledge of all circulating viruses. In addition, as it will be some time before any vaccine is implemented on a large scale, further genetic drift, the introduction of other subtypes, and broadening of the diversity are likely trends that will ultimately impact the quality of the match between the vaccine sequence and the target epidemic. In a separate analysis of all available subtype C fulllength sequences, Gaschen et al. 34 found that the median percent similarity between C clade sequences and the C consensus sequence was 95.4% in p24. This was not markedly different from Du422 p24, which was 94.8% similar to C clade sequences. A comparison of C clade gp160 sequences with the C consensus demonstrated 87.5% similarity, in contrast to 81.3% similarity when Du422 gp160 was compared with clade C gp160s. Although the env gene, as the region with the greatest diversity, would have the most potential benefit from creating a consensus sequence, it is likely that manipulations of Env to improve its antigenicity (e.g., see Reitter et al. 35 and Earl et al. 36 ) will have greatest impact on the performance of an Envbased vaccine.
The sequence survey strategy was designed to improve the efficiency of data acquisition. The six amplicons were each designed to approximate the length of a DNA segment that can be reliably sequenced. The major replicative genes are represented in the sequence, spanning across the genome to allow the assessment of intersubtype recombinants. The length-variable regions of env were avoided so that bulk sequence could be used without loss of register. Representative candidate genes from currently circulating viruses were identified and characterized and have been included in candidate vaccines. Given the unknown impact sequence diversity will have on vaccine efficacy, there is a parallel need to maximize the magnitude of the immune response to any vaccine so as to reduce the potential impact of this diversity.
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